Nigel J. Waters

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Blood · 2013 · 725 citations · Full text

Medicine, Oncology, Pharmacology +11

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima et al. · Molecular Cancer Therapeutics · 2014 · 522 citations

Medicine, Oncology, Pharmacology +14

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

Life Sciences, Molecular Biology, Oncology +10

Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

R. Scott Obach, Franco Lombardo, Nigel J. Waters · Drug Metabolism and Disposition · 2008 · 454 citations

Pharmacy, Pharmacokinetics, Pharmacology +14